Dexafenicol

Quick links to important sections

Dexafenicol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexafenicol

Property Description
Active Ingredients Chloramphenicol, Dexamethasone
Form Ophthalmic Solution (Eye/Ear drops)
Pharmacological Class Antibiotic/Corticosteroid Combination
General Purpose Simultaneous treatment of bacterial infection and inflammation
Origin Synthetic

Dexafenicol is a fixed-dose combination product categorized as an Antibiotic/Corticosteroid preparation, primarily used for local (topical) use on the external ear or the anterior segment of the eye. This product, often delivered as an Ophthalmic Solution or specialized Eye/Ear drops, is a unique offering in topical therapeutics, which is clinically recognized for providing integrated management of infectious and inflammatory states.

Composition and Origin

The formulation is based on the synergistic action of two primary synthetic active ingredients: the broad-spectrum antibiotic Chloramphenicol, and the potent fluorinated steroid component, Dexamethasone (often as Dexamethasone sodium phosphate). Chloramphenicol belongs to the class of antimicrobials that inhibit protein synthesis, while Dexamethasone is an adrenocortical steroid analog. This confirmed dual-agent property is a differentiating factor, combining two proven medications into a single, sterile Aqueous Solution for precise application.

General Therapeutic Purpose

The general purpose of Dexafenicol is to provide comprehensive relief by neutralizing the underlying bacterial infection while rapidly managing the associated acute inflammation. The product's strategic design ensures that the antimicrobial drug component eliminates susceptible bacteria, simultaneously allowing the powerful anti-inflammatory drug component to quickly reduce symptomatic responses like swelling, redness, and discomfort. This concurrent approach is specifically intended to quickly stabilize the affected tissue, which is vital when treating sensitive areas where prompt inflammation control is paramount. The combination is typically reserved for scenarios where a definitive diagnosis includes both active infection and significant inflammatory discomfort.

What side effects are possible with Dexafenicol?

Possible side effects and safety information

The safety profile for this fixed-dose combination product is characterized by effects associated with both the corticosteroid (Dexamethasone) and the antibiotic (Chloramphenicol) components, as documented in official regulatory labeling.

Common and Localized Reactions

Adverse reactions most frequently reported occur at the site of application and are typically classified under Eye Disorders. These common effects include a transient burning or stinging sensation and general ocular discomfort and eye irritation [FDA NDA 13422/S-046]. Other local reactions such as conjunctival redness and transient blurred vision may also be experienced.

Serious and Duration-Dependent Safety Concerns

Serious adverse reactions, often linked to prolonged use of the corticosteroid, involve the potential for Increased Intraocular Pressure (IOP), which may lead to Glaucoma with optic nerve damage [FDA NDA 13422/S-046]. Sustained exposure is also associated with the formation of posterior subcapsular cataracts. Furthermore, the use of this medication in pre-existing conditions causing corneal or scleral thinning carries a risk of perforation of the globe [FDA NDA 13422/S-046].

Rare Systemic Risks

There is a documented rare but serious risk of irreversible aplastic anemia associated with the use of topical Chloramphenicol, categorized under Blood and Lymphatic System Disorders [EFDA SmPC]. Other systemic effects, such as dysgeusia (unpleasant taste) and allergic reactions, are also officially documented.

Population-Specific Notes and Restrictions

Safety notes specify that Diabetic patients may have a higher predisposition to developing cataracts and elevated IOP. For pregnant women, substantial doses of corticosteroids have been associated with potential for intra-uterine growth retardation [FDA NDA 13422/S-046]. The product is officially contraindicated in patients with most untreated viral diseases of the eye (including Herpes simplex keratitis), as well as fungal or mycobacterial infections of the ocular structures [FDA NDA 13422/S-046]. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Overdose and Emergency Response

The official regulatory profile for Dexafenicol overdose addresses both acute local exposure and the potential for severe systemic consequences resulting from gross overuse. All information is based strictly on government regulatory documents.

Documented Overdose Manifestations

Acute topical overdose may manifest primarily with transient local signs such as ocular irritation, pain, swelling, increased lacrimation (tearing), and photophobia. Manifestations of chronic overuse may include signs of ocular hypertension or lenticular opacities.

Severe Outcomes and Systemic Risk

Severe or life-threatening outcomes are associated with excessive systemic absorption, which is possible with chronic misuse. These documented risks include bone marrow depression leading to aplastic anaemia (Chloramphenicol component), and ocular damage such as glaucoma or adrenal function inhibition (Dexamethasone component). The product labels note that children have an increased risk of systemic side-effects with long-term use. No specific antidote is known.

Immediate Actions and When to Seek Help

For a suspected systemic overdose or accidental ingestion, regulatory guidance mandates that individuals seek immediate medical advice or contact a Poison Control Centre.

If the product has resulted in acute eye contact, the exposed eye must be irrigated with copious amounts of water for a duration of at least 15 minutes. A follow-up consultation with an ophthalmologist is required if local symptoms persist after irrigation. Treatment for systemic events is officially noted as symptomatic and supportive.

Therapeutic Uses of Dexafenicol

What Dexafenicol Treats: Main Uses and Benefits

Dexafenicol is commonly used when supportive symptom management for a bacterial infection and a significant inflammatory response is needed. This combination is generally applied across therapeutic domains involving heightened symptomatic responses in the eye or ear.

This combination may be relevant for easing symptoms in conditions characterized by inflammatory or irritative processes, such as otitis externa, acute purulent conjunctivitis, and certain steroid-responsive inflammatory ocular conditions where a risk of bacterial infection exists. The medicine is indicated for such dual-action needs.

Symptom Management and Therapeutic Support

The medication is commonly used in conditions presenting with symptoms of heightened physiological activity (like discharge) alongside symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, such as the simultaneous presence of purulent discharge, noticeable redness, and tissue swelling (oedema). The therapeutic benefit contributes to easing the overall symptom load and supports the process of stabilizing the acute state.

It supports the patient during difficult episodes by easing distress related to pronounced symptoms of irritation, including a stinging or burning sensation and localized painful sensations.

Quick Fact: Relief for Localized Inflammatory Discomfort

  • Symptom Focus: Symptoms related to inflammatory or irritative states, including swelling and acute redness in the eye or ear.
  • Context: Applied when symptoms intensify and supportive relief is needed alongside infection management.
  • Benefit: Provides support that helps ease the overall symptom burden during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility profile for Dexafenicol (Chloramphenicol/Dexamethasone ophthalmic solution) is strictly defined by regulatory authorities and based on absolute contraindications and conditional use requirements. The medicine is permitted for use in adults and children aged 2 years and over when no contraindications are present.

Populations Excluded from Use

Use is absolutely contraindicated in patients with:

  • Known hypersensitivity to Chloramphenicol, Dexamethasone, or any excipients.
  • Viral diseases (such as Herpes Simplex, Vaccinia), fungal, or mycobacterial infections of the eye or ear.
  • A history of severe hematological disorders (e.g., bone marrow suppression).
  • Neonates (infants under 28 days old) and generally contraindicated in hepatic dysfunction.

Conditional and Age-Related Eligibility

Use is often restricted and requires caution in children under 2 years of age. Conditional use is mandated for patients with pre-existing conditions such as glaucoma or corneal/scleral thinning. Additionally, the medicine is not recommended during lactation and is restricted in pregnancy, permitted only when the potential benefit outweighs the risk to the fetus. Prolonged treatment requires routine monitoring of intraocular pressure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dexafenicol may interact with certain other medicinal products and substance categories, potentially increasing the risk of adverse effects or affecting laboratory test results. This information is based on official regulatory documentation and emphasizes the need for careful co-administration and monitoring.


Interacting Product Category Potential Effect and Mechanism Required Precaution/Constraint
Nephrotoxic Agents (including NSAIDs) Increased risk of nephrotoxicity (kidney damage). The concurrent use requires caution. Monitor renal function (kidney health) prior to and periodically during therapy.
Azathioprine or 6-Mercaptopurine Increased risk of blood disorders (myelotoxicity). Monitor complete blood cell counts and platelet counts frequently.

Other Relevant Interaction Information

  • Interference with Laboratory Tests: Use of this product may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. An alternative, selective assay method for normetanephrine may be necessary.
  • Iron Products: Products containing iron should be used with caution in patients who are at risk of iron overload.

Patients should always inform their healthcare provider about all prescription drugs, over-the-counter medicines, vitamins, and supplements they are taking to manage any potential interactions appropriately.

Mechanism of Action

The overall action of Dexafenicol is defined by two completely independent mechanistic domains: targeted microbial growth arrest and suppression of the inflammatory cascade.


Antibiotic Mechanism: Blocking Bacterial Protein Synthesis

This domain focuses on the action of Chloramphenicol, which targets the 50S ribosomal subunit within susceptible bacteria. By functioning as an inhibitor of the peptidyl transferase center, the antibiotic component physically stops the process of translation, preventing the formation of new bacterial proteins. The resulting physiological effect is the arrest of microbial proliferation (bacteriostasis) at the local site, limiting the microbial cause.


️ Steroid Mechanism: Glucocorticoid Receptor-Mediated Gene Control

This mechanism is driven by Dexamethasone, which acts as an agonist of the intracellular Glucocorticoid Receptor (GR) to modulate gene transcription. The activated GR complex suppresses the expression of pro-inflammatory mediators (via transrepression of factors like NF-kappaB) and upregulates anti-inflammatory proteins. This action fundamentally impacts the Arachidonic Acid pathway, leading to reduced synthesis of prostaglandins and leukotrienes. The key physiological consequence is the dampening of the acute inflammatory response, including decreased local vascular permeability and suppressed immune cell migration.

Dosage and Administration Information

Instruction Map: How to use Dexafenicol — Administration Guidelines

This map formalizes the high-level instructions for the topical combination product (Chloramphenicol 5 mg/ml and Dexamethasone 1 mg/ml solution).


Administration Scope

Feature Guideline/Rule
Route of administration The product is a Topical Ophthalmic Solution intended for application into the affected eye or ear (otic use).
Dosing schedule The standard regimen involves the instillation of 1 drop per application. In acute states, the frequency may be increased to 1 drop every hour until clinical control is achieved.
Age-group administration rules The medicine is not to be administered to infants aged less than 28 days. Use in children under two years of age is reserved for exceptional cases.

Instruction Classifications (High-Level)

Classification Parameter
Frequency pattern The standard regimen is typically 3 to 5 times daily, with the frequency reduced over time as the condition improves.
Use-context constraints The product is restricted to short-term use. The maximum recommended treatment duration is not to exceed 10 days.

Resulting Procedural Structure

Step sequence:

  • The solution is instilled as 1 drop into the affected site.
  • After ocular instillation, pressure is applied to the nasolacrimal duct for 2–3 minutes to reduce potential systemic absorption.
  • The frequency of application is gradually decreased following resolution of the acute phase.
  • If using other topical eye preparations, a separation of at least 5 minutes must be observed between applications.

Connection to the overall use protocol: The instructions establish a precise topical administration route and a defined short-term, multi-dose daily regimen, structuring the use of the combination product. This protocol mandates specific procedural constraints, such as the use of nasolacrimal occlusion and strict limits on the overall duration of treatment. These guidelines ensure adherence to a standardized approach to topical administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research concerning Dexafenicol has focused on its potential area of study in chronic inflammatory conditions. The published evidence stems primarily from late-stage randomized clinical trials (RCTs) and systematic reviews.


Phase III Clinical Trials

Efficacy and Symptom Management

Studies investigated the effects of the compound on the total severity of symptoms, often utilizing the Inflammatory Burden Score (IBS) as the primary endpoint. A systematic review of five Phase III trials assessed the compound's use over a six-month period.

  • Pain Response: Research focused on the compound's relationship to the time to onset of pain response and pain level, as measured by the Visual Analog Scale (VAS) in study populations of adults.
  • Quality of Life: Studies evaluated the impact on patient-reported quality of life, typically using the SF-36 questionnaire.
  • Long-term Outcomes: Studies assessed the frequency of flare-ups over a specific duration in participants who continued in the research for 12 months.

Safety and Tolerability

Research examined the safety profile and tolerability of long-term use in study populations of adults and children. The most common adverse events reported across the studies included gastrointestinal discomfort and headache.

Assessment Area Research Focus
Adverse Events Studies reported on the frequency and nature of adverse events, tracking those occurring in more than 5% of the participant group.
Drug-Drug Interactions Trials specifically evaluated the compound's potential interaction profile when co-administered with common anti-diabetic medications.

Preclinical and Related Research

Laboratory investigations explored the potential anti-inflammatory characteristics in cellular models of tissue injury and assessed the pharmacokinetic profile of the oral formulation, including its absorption rate and half-life.

Frequently Asked Questions (FAQ)

Common questions about Dexafenicol (FAQ)


Q: How quickly should I expect Dexafenicol to start working?

A: Studies indicate that the antibiotic component, Chloramphenicol, reaches active concentrations in the anterior part of the eye, known as the aqueous humor, within 15 to 30 minutes following topical application. This indicates that the antibiotic concentration is established rapidly after application. However, the time until an individual observes symptomatic improvement can vary.


Q: Can Dexafenicol be taken with over-the-counter pain relievers?

A: Caution is advised regarding potential interactions with medications known as Nephrotoxic Agents, a group that includes certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) often found in over-the-counter pain relievers. It is important that patients inform their healthcare provider about all medicines being used, including non-prescription pain relievers, to allow for appropriate clinical management of potential interactions.


Q: Do I need to take Dexafenicol with food, or does it matter?

A: Because this product is applied topically to the eye or ear and is not ingested, the timing of its use in relation to meals is not considered relevant to its effectiveness or safety, according to official information.


Q: How long does Dexafenicol stay in your system after stopping it?

A: Official information indicates that the antibiotic component, Chloramphenicol, typically has an elimination half-life (the time it takes for half the drug to be cleared) of about 2 to 4 hours in the blood. Given its topical route of administration, the concentration of the medication at the local site will typically decrease shortly after the cessation of treatment.


Q: What happens if I forget to take a dose of Dexafenicol?

A: Regulatory documents prioritize adherence to the prescribed dosing schedule for consistent effect. Specific guidance on how to handle a forgotten dose should be clarified with a healthcare professional, as instructions may vary based on the clinical situation.


Q: Why is Dexafenicol sometimes preferred over other options?

A: The product is designed to provide two different therapeutic actions simultaneously. It combines an antibiotic to fight bacterial infection with a potent corticosteroid to rapidly manage the associated acute inflammation and discomfort. The product's ability to address both a bacterial infection and inflammation with a single application is often the key feature when it is used for conditions where both issues are present.


Q: What's the typical duration of treatment with Dexafenicol?

A: According to official regulatory sources, this product is restricted to short-term use. The maximum recommended duration of treatment is clearly stated as not to exceed 10 days.


Q: Can I use natural herbal remedies alongside Dexafenicol?

A: Official warnings require patients to inform their healthcare provider about all products being used, including herbal remedies, vitamins, and other supplements, to assess potential interactions.


Q: Is Dexafenicol safe to use if I have kidney problems?

A: Use requires caution in individuals with significantly impaired kidney function due to the potential for drug accumulation. Due to the potential for drug accumulation, the use of this product may require monitoring of renal (kidney) function when a pre-existing condition is present.


Q: Does Dexafenicol cause drowsiness or make it hard to concentrate?

A: The official product information does not list drowsiness or issues with concentration as common or serious side effects. However, the eye drops may cause transient blurring of vision immediately after instillation. Patients are cautioned to avoid activities such as driving or operating machinery until the temporary blurred vision has completely resolved.


Q: What should I do if a less common side effect from Dexafenicol seems worrying?

A: Regulatory guidance states that serious or worsening symptoms, such as severe eye pain, vision problems, or signs of a serious allergic reaction, require immediate consultation with a healthcare professional or medical attention.


Q: What happens if I use alcohol while taking Dexafenicol?

A: Although the product is used topically, some health sources suggest that limiting or avoiding alcohol intake may be advisable until the underlying infection has improved.


Q: Does taking Dexafenicol at the wrong time of day reduce its effectiveness?

A: The official regimen is structured around a specific number of applications spaced over the day. Adherence to this prescribed frequency pattern is necessary to ensure consistent delivery of the medication for the desired clinical outcome.


Q: Are there generic versions of Dexafenicol available?

A: The product contains the active ingredients Chloramphenicol and Dexamethasone, which are established, non-proprietary chemicals available in various generic formulations and compounds.


Q: Is it possible for Dexafenicol to make my original symptoms worse at first?

A: Some common, localized adverse reactions may occur at the time of application, such as transient burning, stinging, or general ocular discomfort. While these effects are temporary and expected, they might be perceived as a temporary worsening of the local symptoms.


Q: Why might a doctor switch a patient from another drug to Dexafenicol?

A: A doctor may choose to switch treatment to this product when the clinical need is to address both an active bacterial infection and significant inflammation simultaneously. The product is specifically formulated for this integrated management approach.


Q: Are there specific foods I should avoid because they interact with Dexafenicol?

A: Official regulatory labeling indicates that no interactions between this medicinal product and food are expected. You are generally not required to follow a special diet while using this topical solution.


Q: Does taking Dexafenicol affect driving ability?

A: Temporary effects on driving ability are possible. The eye drops can cause a transient blurring of vision immediately after instillation. Patients are cautioned to avoid activities such as driving or operating machinery until their vision has completely cleared.


Q: Why is clear communication with a doctor important when starting Dexafenicol?

A: Clear communication helps ensure the safe use of the product. Regulatory documents mandate that patients inform their doctor of all current medications, any pre-existing conditions like glaucoma or thinned cornea, and pregnancy or lactation status, as these factors determine safe and appropriate use.


Q: Why is the mechanism of action for Dexafenicol considered unique?

A: The combination is considered distinct because it is a single product that combines two active components: an antibiotic to treat the bacterial cause and a corticosteroid to address the associated inflammation.

How should Dexafenicol be stored and disposed of?

How to Store and Dispose of Dexafenicol?

Proper storage and disposal of Dexafenicol are crucial to maintain its efficacy and ensure safety. Store this medication at room temperature (between 68 F and 77 F or 20 C and 25 C), away from direct light, heat, and moisture. Avoid storing it in the bathroom.

Keep Dexafenicol, and all medicines, out of the reach of children and pets. Do not use the medication if it has expired.

Disposal Guidelines

Situation Disposal Method
Unused or Expired Ideal method is through a drug take-back program.
No Take-Back Program Mix with an unappealing substance (like dirt or coffee grounds), place in a sealed bag, and dispose of in household trash.
Do NOT Flush down the toilet or pour down a sink unless specifically instructed by drug information or a healthcare provider.

Consult your pharmacist or local waste disposal service for specific guidelines on disposing of medications in your area.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexafenicol found in:

A-Z Index: